Spero Therapeutics Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Der Gewinn je Aktie von Spero Therapeutics wird voraussichtlich um 47.6% pro Jahr steigen.
Wichtige Informationen
n/a
Wachstumsrate der Gewinne
47.61%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 25.2% |
| Wachstumsrate der Einnahmen | n/a |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | None |
| Zuletzt aktualisiert | n/a |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy
Summary Spero Therapeutics' lead asset is an oral carbapenem tebipenem for cUTI. This asset achieved Phase 3 noninferiority. In fact, this data supports GSK’s NDA resubmission strategy. The prior FDA setback from ADAPT-PO was addressed through PIVOT-PO. The new PIVOT-PO trial was actually stopped early after strong interim efficacy results. So, I believe their data is quite favorable this time. Also, SPRO’s partnership economics are meaningful. They can soon receive sizable resubmission milestone payments and royalties tied to commercialization. In my view, SPRO’s current valuation seems too low relative to the TAM they can unlock with tebipenem. So, I rate them a speculative 'Buy' at these levels. Read the full article on Seeking AlphaSpero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 26%
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders would be excited to see that the share price has had a great...
Positive Phase III Efficacy Will Unlock Expanded Antibiotic Markets
The downward revision in Spero Therapeutics’ consensus price target largely reflects declines in its future P/E multiple and net profit margin, resulting in a lower fair value estimate of $4.00. What's in the News The phase III PIVOT-PO trial of tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), was stopped early due to efficacy, following an Independent Data Monitoring Committee recommendation.Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?
NasdaqGS:SPRO 1 Year Share Price vs Fair Value Explore Spero Therapeutics's Fair Values from the Community and select...Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price
With a price-to-sales (or "P/S") ratio of 3.1x Spero Therapeutics, Inc. ( NASDAQ:SPRO ) may be sending very bullish...
Successful Phase III Trial Will Redefine Treatment For Complicated UTIs
Successful PIVOT-PO trial and regulatory approval could propel revenue growth, leveraging a strategic partnership with GSK for commercialization.Spero Therapeutics, Inc. (NASDAQ:SPRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
To the annoyance of some shareholders, Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shares are down a considerable 27% in...Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
Summary Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical due to rising resistance to current oral treatments for complicated urinary tract infections. Tebipenem's success in the confirmatory phase 3 trial is highly probable, given its prior phase 3 success and publication in NEJM. Despite risks, SPRO's valuation is attractive, with significant upside potential from tebipenem milestones and possible pipeline progress. Read the full article on Seeking AlphaThere Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding
Spero Therapeutics, Inc.'s ( NASDAQ:SPRO ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong buy...Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price
Spero Therapeutics, Inc.'s ( NASDAQ:SPRO ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy...Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Summary Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential. Spero has excellent downside protection and additional upside from the payments from the Tebipenem HBr deal with GSK. Spero's significant undervaluation and potential path forward are highlighted in the peer comparison. Read the full article on Seeking AlphaSpero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shares have continued their recent momentum with a 27% gain in the last month...Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
The Spero Therapeutics, Inc. ( NASDAQ:SPRO ) share price has done very well over the last month, posting an excellent...Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates
Today is shaping up negative for Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders, with the analysts delivering a...Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth
Those holding Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shares would be relieved that the share price has rebounded 26...Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders will have a reason to smile today, with the analysts making...We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2026 | 61 | 15 | 7 | 7 | N/A |
| 12/31/2025 | 67 | 9 | -13 | -13 | N/A |
| 9/30/2025 | 41 | -44 | -28 | -28 | N/A |
| 6/30/2025 | 49 | -54 | -32 | -32 | N/A |
| 3/31/2025 | 45 | -70 | -33 | -33 | N/A |
| 12/31/2024 | 48 | -69 | -23 | -23 | N/A |
| 9/30/2024 | 106 | 4 | -18 | -18 | N/A |
| 6/30/2024 | 118 | 17 | -14 | -14 | N/A |
| 3/31/2024 | 111 | 23 | -14 | -14 | N/A |
| 12/31/2023 | 104 | 23 | -33 | -33 | N/A |
| 9/30/2023 | 78 | -2 | 29 | 29 | N/A |
| 6/30/2023 | 54 | -10 | 12 | 12 | N/A |
| 3/31/2023 | 54 | -27 | 8 | 8 | N/A |
| 12/31/2022 | 54 | -46 | -8 | -8 | N/A |
| 9/30/2022 | 9 | -102 | -80 | -80 | N/A |
| 6/30/2022 | 10 | -113 | -84 | -84 | N/A |
| 3/31/2022 | 13 | -103 | -77 | -77 | N/A |
| 12/31/2021 | 18 | -90 | -64 | -64 | N/A |
| 9/30/2021 | 17 | -79 | -53 | -53 | N/A |
| 6/30/2021 | 18 | -76 | -70 | -70 | N/A |
| 3/31/2021 | 15 | -74 | -78 | -78 | N/A |
| 12/31/2020 | 9 | -79 | -86 | -86 | N/A |
| 9/30/2020 | 11 | -85 | -87 | -87 | N/A |
| 6/30/2020 | 12 | -84 | -75 | -75 | N/A |
| 3/31/2020 | 12 | -80 | -63 | -62 | N/A |
| 12/31/2019 | 18 | -61 | N/A | -50 | N/A |
| 9/30/2019 | 16 | -47 | N/A | -46 | N/A |
| 6/30/2019 | 12 | -39 | N/A | -42 | N/A |
| 3/31/2019 | 11 | -36 | N/A | -39 | N/A |
| 12/31/2018 | 4 | -42 | N/A | -40 | N/A |
| 9/30/2018 | 3 | -46 | N/A | -39 | N/A |
| 6/30/2018 | 3 | -47 | N/A | -44 | N/A |
| 3/31/2018 | 3 | -50 | N/A | -44 | N/A |
| 12/31/2017 | 2 | -46 | N/A | -39 | N/A |
| 9/30/2017 | 1 | -40 | N/A | -36 | N/A |
| 6/30/2017 | 1 | -35 | N/A | -32 | N/A |
| 3/31/2017 | 0 | -30 | N/A | -29 | N/A |
| 12/31/2016 | 0 | -30 | N/A | -29 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von SPRO über der Sparquote liegt (3.5%).
Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von SPRO schneller wachsen werden als der Markt US
Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von SPRO in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von SPRO schneller wachsen werden als der Markt von US.
Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von SPRO schneller wachsen werden als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SPRO in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/24 21:20 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Spero Therapeutics, Inc. wird von 6 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Esther Lannie Hong | Berenberg |
| Jason Matthew Gerberry | BofA Global Research |
| Esther Lannie Hong | Brean Capital Historical (Janney Montgomery) |